General Information of Drug (ID: DMDZY54)

Drug Name
Fremanezumab
Synonyms Fremanezumab [INN]; Fremanezumab [USAN]; UNII-PF8K38CG54; PF8K38CG54; TEV-48125; PF-04472429
Indication
Disease Entry ICD 11 Status REF
Hyperprolactinaemia 5A60.1 Approved [1]
Drug Type
Antibody
Sequence
>heavy chain
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWISWVRQAPGKGLEWVAEIRSESDASAT
HYAEAVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLAYFDYGLAIQNYWGQGTLVTV
SSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNST
FRVVSVLTVVHQDWLNGKEYKCKVSNKGLPSSIEKTISKTKGQPREPQVYTLPPSREEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQ
GNVFSCSVMHEALHNHYTQKSLSLSPGK
>Light chain
EIVLTQSPATLSLSPGERATLSCKASKRVTTYVSWYQQKPGQAPRLLIYGASNRYLGIPA
RFSGSGSGTDFTLTISSLEPEDFAVYYCSQSYNYPYTFGQGTKLEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
ADMET Property
Clearance
The clearance of drug is 0.141 L/day [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 31 - 39 days [3]
Metabolism
The drug is metabolized via the enzymatic proteolysis into smaller peptides and amino acids [2]
Vd
The volume of distribution (Vd) of drug is 6 L [2]
Cross-matching ID
DrugBank ID
DB14041
TTD ID
D08PLK

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcitonin gene-related peptide receptor (CGRPR) TTY6O0Q CALRL_HUMAN Modulator [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 FDA Approved Drug Products: Ajovy (fremanezumab-vfrm) subcutaneous injection
3 A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. Cephalalgia. 2018 Jan 1:333102418771376. doi: 10.1177/0333102418771376.